Pacific Biosciences of California, Inc.

NasdaqGS:PACB Voorraadrapport

Marktkapitalisatie: US$446.9m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Pacific Biosciences of California Beheer

Beheer criteriumcontroles 2/4

De CEO Pacific Biosciences of California's is Christian O. Henry, benoemd in Sep2020, heeft een ambtstermijn van 4.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.05M, bestaande uit 8.6% salaris en 91.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.14% van de aandelen van het bedrijf, ter waarde $ 660.43K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 11.7 jaar.

Belangrijke informatie

Christian O. Henry

Algemeen directeur

US$8.0m

Totale compensatie

Percentage CEO-salaris8.6%
Dienstverband CEO4.1yrs
Eigendom CEO0.1%
Management gemiddelde ambtstermijn3.9yrs
Gemiddelde ambtstermijn bestuur11.7yrs

Recente managementupdates

Recent updates

Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Sep 20
Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Aug 21

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

Jul 02
Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Jun 08
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Jun 03

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

Apr 25
These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16
It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01
With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18
What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13
Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28
The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06
Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29
Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Analyse CEO-vergoeding

Hoe is Christian O. Henry's beloning veranderd ten opzichte van Pacific Biosciences of California's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$400m

Mar 31 2024n/an/a

-US$297m

Dec 31 2023US$8mUS$695k

-US$307m

Sep 30 2023n/an/a

-US$309m

Jun 30 2023n/an/a

-US$319m

Mar 31 2023n/an/a

-US$321m

Dec 31 2022US$7mUS$667k

-US$314m

Sep 30 2022n/an/a

-US$299m

Jun 30 2022n/an/a

-US$206m

Mar 31 2022n/an/a

-US$175m

Dec 31 2021US$3mUS$650k

-US$181m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$59m

Dec 31 2020US$13mUS$195k

US$29m

Sep 30 2020n/an/a

-US$46m

Jun 30 2020n/an/a

-US$51m

Mar 31 2020n/an/a

-US$53m

Dec 31 2019US$100kn/a

-US$84m

Sep 30 2019n/an/a

-US$115m

Jun 30 2019n/an/a

-US$111m

Mar 31 2019n/an/a

-US$109m

Dec 31 2018US$88kn/a

-US$103m

Compensatie versus markt: De totale vergoeding ($USD 8.05M ) Christian O. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).

Compensatie versus inkomsten: De vergoeding van Christian O. is gestegen terwijl het bedrijf verliesgevend is.


CEO

Christian O. Henry (56 yo)

4.1yrs

Tenure

US$8,046,575

Compensatie

Mr. Christian O. Henry, MBA, served as Independent Director at CM Life Sciences III Inc. since April 07, 2021 until December 2021. He has been President and Chief Executive Officer at Pacific Biosciences o...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Christian O. Henry
President4.1yrsUS$8.05m0.14%
$ 637.1k
Susan Kim
Chief Financial Officer4.1yrsUS$2.52m0.036%
$ 159.6k
Mark Van Oene
Chief Operating Officer3.8yrsUS$4.60m0.12%
$ 518.8k
Jeff Eidel
Chief Commercial Officer2.2yrsUS$2.53m0.050%
$ 221.8k
Stephen Turner
Co-Founder24.3yrsUS$466.76kgeen gegevens
Michele Farmer
VP & Chief Accounting Officer3.4yrsgeen gegevens0.013%
$ 59.4k
Brett Atkins
General Counsel & Corporate Secretaryno datageen gegevensgeen gegevens
Natalie Welch
Chief People Officerno datageen gegevensgeen gegevens

3.9yrs

Gemiddelde duur

49.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PACB wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Christian O. Henry
President6.3yrsUS$8.05m0.14%
$ 637.1k
William Ericson
Independent Director20.8yrsUS$259.00k0.0069%
$ 30.8k
Lucy Shapiro
Independent Director12.1yrsUS$255.00k0%
$ 0
John Milligan
Independent Chairman11.3yrsUS$297.00k0.040%
$ 180.4k
Harry Gray
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Joseph Bonventre
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Randall Livingston
Independent Director15.8yrsUS$265.00k0%
$ 0
Harold Craighead
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Roger Kornberg
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Watt Webb
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Kenneth Johnson
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Jay Shendure
Chairman of Scientific Advisory Board1.9yrsgeen gegevensgeen gegevens

11.7yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PACB zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.7 jaar).